Company intelligence / Profile preview

Shanghai Innogen Pharmaceutical Technology Co., Ltd.

Shanghai, Shanghai, Chinachinesebiotech.com ↗

Ownership: Private
Development stage: NDA

Overview

Efsubaglutide Alfa, a long‑acting GLP‑1 receptor agonist injection branded as Yinuoqing, was approved in China in early 2025 for type 2 diabetes. Clinical trials showed strong efficacy with HbA1c reduction up to −2.2% at week 24 and significant weight loss with minimal side effects. The company has additional pipeline assets targeting metabolic diseases and NASH/MASH at various clinical stages.

Therapeutic areas: GastroenterologyEndocrinology
Modalities: Recombinant proteinsFusion proteinsSmall molecules
Industry: Biotech

Drug pipeline

2 assets

Diabegone

Preclinical

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Shanghai Innogen Pharmaceutical Technology Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Innogen Pharmaceutical Technology Co., Ltd..

Explore the full profile